FDA warned Biomedical Research Laboratories that website claims make six of its supplements unapproved new drugs.
What happened
FDA reviewed the company's websites (nativeorigins.com, brlsports.com, brlscience.com) and a Native Origins Facebook page in May 2021. FDA found the sites take orders for Calm Legs, Flexify, Collagen Peptides, Prohemia, Altitude RX and Trimmunity and promote them as treatments for diseases such as restless legs syndrome, arthritis, anemia and altitude sickness. FDA said those claims make the products drugs, and because they are not FDA-approved, selling them is illegal.
What FDA found
Website claims that Calm Legs relieves restless legs syndrome make it an unapproved drug.
Section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]; sections 201(p), 301(d), 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]Claims that Flexify reduces arthritis and joint pain make it an unapproved drug.
21 U.S.C. 321(g)(1)(B), 321(p), 331(d), 355(a)Claims that Collagen Peptides, Prohemia, Altitude RX and Trimmunity treat or prevent diseases (arthritis, anemia, altitude sickness, infection) make them unapproved drugs.
21 U.S.C. 321(g)(1)(B), 321(p), 331(d), 355(a)Calm Legs, Collagen Peptides and Flexify are meant for conditions that need a licensed practitioner, so they cannot carry adequate directions for a layperson and are misbranded.
Section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5Selling these misbranded drugs in interstate commerce violates the Act.
Section 301(a) of the Act [21 U.S.C. 331(a)]
What FDA wants
FDA asks the company to write back within 15 working days describing the specific steps taken to fix the violations and prevent them from recurring, with supporting documents, or to explain why it believes the products are compliant.
Who should pay attention
- supplement brands that make disease-treatment claims on their websites
- retailers and online marketplaces listing RLS, arthritis or anemia supplements
- label and website reviewers at supplement companies
This is a summary. Read the original letter on fda.gov.